If you are considering psychedelic-assisted treatment in Slovakia (for yourself or for someone close to you), the defining fact of July 2026 is a negative one. Among its neighbours, Slovakia is the country where the health-technology assessment came back against public payment for esketamine, and no funded route was built around that verdict. What remains is an exception mechanism with no guarantee, a thin private market, and the border. This guide covers each honestly; you can begin orienting yourself with our eligibility check.
TL;DR Spravato (esketamine) is registered in Slovakia but not categorised: the HTA institute NIHO recommended refusing reimbursement unless the indication was restricted to patients aged 18–64 without psychotic symptoms and the maker granted a discount to meet cost-effectiveness law, and no categorisation followed. Coverage is therefore only possible as a case-by-case insurer exception, with no legal entitlement. Hungary, Romania, Croatia and Czechia all fund esketamine; Slovakia does not. Privately, TMS clinic in Bratislava treats treatment-resistant depression with TMS and names ketamine infusion therapy as an alternative, but no Slovak clinic publishes a structured ketamine programme. Czech self-pay programmes are the pragmatic fallback. Psilocybin and MDMA are research-only.
At a glance
| Route | Substance | Status in Slovakia | Who qualifies | Cost |
|---|---|---|---|---|
| Reimbursed esketamine | Esketamine (Spravato) | Registered but not categorised: no standard reimbursement | – | Self-pay, unless an exception is granted |
| Insurer exception | Esketamine (Spravato) | Possible case by case for non-categorised drugs; prior approval required | Decided by the insurer on the treating doctor's request; no legal entitlement | Covered only if approved |
| Private care | TMS (device), ketamine named as alternative | TMS clinic in Bratislava treats pharmacotherapy-resistant depression; no published ketamine programme in Slovakia | Clinic screening; failed pharmacotherapy | Self-pay |
| Cross-border | Ketamine (KAP) | Legal self-pay programmes in Czechia | Czech clinics' own screening | Self-pay |
| Psilocybin / MDMA therapy | Psilocybin, MDMA | Research only; no legal route | – | – |
The NIHO verdict: why there is no funded route
Janssen applied to have Spravato categorised (the Slovak mechanism for public reimbursement) proposing a payment of 222.64 euros per 28 mg device for adults with treatment-resistant depression. The National Institute for Value and Technologies in Healthcare (NIHO) assessed the application and recommended refusing it unless two conditions were met: the covered population narrowed to patients aged 18–64 without psychotic symptoms, and a confidential discount deep enough to satisfy the cost-effectiveness criteria of the pricing law, reflecting what NIHO called large uncertainty in the clinical-benefit and cost-effectiveness evidence. It also recommended reassessing the drug two years after any categorisation (NIHO assessment summary; full report, PDF). NIHO's own experts, notably, wanted the drug available and predicted meaningful clinical benefit: the objection was price against evidence, not the medicine itself.
No categorisation followed. That single fact separates Slovakia from every neighbour in this series: Czechia reimburses Spravato, Hungary supports it at 100% on specialist prescription, Romania funds it through a national subprogram, Croatia pays through its expensive-drugs list. In Slovakia the drug is registered and the state drug agency ŠÚKL publishes patient guidance for it (ŠÚKL patient booklet, PDF), but nobody is obliged to pay for it.
The exception route: possible, not promised
Slovak insurers can cover a non-categorised drug through a prior-approval exception (liek na výnimku): your treating doctor applies, the insurer decides, and no legal entitlement to approval exists (Union: reimbursement of registered non-categorised drugs). The health-care surveillance authority has criticised the exception rules as vague and in need of legislative repair (ÚDZS, July 2023), and refusal patterns differ between insurers. What we don't know: no insurer publishes how often Spravato exceptions are requested or approved, and no public record names the facilities that would administer it if one were granted. If you pursue this route, it stands or falls on your psychiatrist's application and documented treatment history: two adequate failed antidepressant trials, in writing.
Private care: a thin market
TMS clinic in Bratislava-Petržalka, an outpatient psychiatric clinic focused on pharmacotherapy-resistant depression, OCD, PTSD and addictions, is the visible private option for treatment-resistant patients; its core offer is transcranial magnetic stimulation, and its patient materials name ketamine infusion therapy alongside TMS as the alternatives when antidepressants fail (TMS clinic FAQ). Note what is missing: no Slovak clinic publicly advertises a structured ketamine or esketamine programme with published screening criteria and prices. Slovak media have documented individual patients obtaining ketamine treatment (Denník N, 2023), but a documented, bookable pathway does not exist in public. The pragmatic alternative many patients weigh is cross-border: Prague's self-pay ketamine-assisted psychotherapy programmes operate openly and screen international patients; see our Czechia guide and the Europe-wide cost comparison. To see who is listed near you, browse providers in Slovakia.
Psilocybin, MDMA and trials
Psilocybin and MDMA remain controlled substances in Slovakia with no medical-access route; anyone selling such therapy today is operating illegally. No recruiting psychedelic trial in Slovakia was listed at the time of writing: watch ClinicalTrials.gov and the EU CTIS registry, browse trial sites in Slovakia, and see our trials guide for how participation works.
What to expect in treatment
Medically reviewed by Dr. Amy Reichelt, PhD, 31 July 2026: this section and the risks section below.
These routes share a shape (medical screening, supervised administration, structured follow-up), but they are not interchangeable: the indication, the schedule, the staffing and the strength of the evidence all differ depending on whether you are prescribed Spravato (esketamine), given ketamine, or entering a legal psychedelic-assisted therapy route, where your country has one. What every route has in common is where it starts. Treatment begins with a screening appointment: the clinician reviews your psychiatric and medication history, checks your cardiovascular health and current medicines, and confirms the diagnosis before anything is scheduled. This is also where contraindications are caught.
On a Spravato day you self-administer the nasal spray in the practice or clinic under supervision, then stay for an observation period of roughly two hours while staff monitor blood pressure, heart rate, sedation, dissociation, breathing and overall recovery. Dissociation, dizziness, sedation, nausea and a temporary rise in blood pressure are common (though they do not occur in everyone), and settle as the drug clears. You must not drive, operate machinery or undertake anything hazardous until the following day, after a night's sleep, so arrange transport home. Induction is typically more frequent at first and then tapers based on measured response. Under the European label, Spravato for treatment-resistant depression is taken alongside a continuing oral SSRI or SNRI antidepressant.
A ketamine infusion for depression is an off-label use of the drug. It is usually given intravenously over about 40 minutes, with vital-sign and psychological monitoring and a recovery period afterwards. Some services offer ketamine-assisted psychotherapy (KAP), which wraps the dosing in preparation and integration sessions with a therapist; others provide ketamine as a medical antidepressant treatment with no psychotherapy component at all, which is worth establishing before you book. Where a legal psychedelic-assisted therapy route exists, and what that route is depends on the country: a clinical trial in most, a regulated programme or compassionate-use scheme in a few; dosing days are long and closely supervised by trained clinical staff, and sit inside a broader plan of preparation, general psychiatric care and integration. In every setting the medicine is one part of the plan: screening, monitoring and follow-up reduce risk but cannot eliminate it, and psychotherapy or integration may help you make sense of what the treatment brings up and apply it afterwards.
Risks and who should not start
These treatments are generally well tolerated under supervision, but they are not for everyone, which is exactly what screening is for. Common, transient effects during or shortly after a session include dissociation (a detached, dreamlike feeling), nausea, mild perceptual changes, and a short-lived rise in blood pressure and heart rate; these resolve as the drug is metabolised. Treatment may be inappropriate, or require particular caution and specialist evaluation, when any of the following apply:
- Uncontrolled hypertension or significant cardiovascular instability, including a history of aneurysmal vascular disease. This is a contraindication for Spravato, because of the temporary rise in blood pressure; the other treatments carry their own cardiovascular assessment.
- A personal or family history of psychosis or bipolar disorder: a particular caution for classic psychedelics such as psilocybin, which legal programmes screen for carefully.
- Pregnancy or breastfeeding.
- Current uncontrolled substance use, a history of ketamine misuse, or a high risk of compulsive use: any of these may make treatment inappropriate or require specialist assessment.
A responsible provider screens for all of these before the first dose. Careful screening, monitoring and follow-up reduce risk; they do not remove it. If a clinic is willing to treat you without that assessment, treat it as a warning sign; see our clinic-choice guide. To see who is listed near you, browse providers in Slovakia.
Reviewer's note. Ketamine, Spravato (esketamine) and psilocybin-assisted therapies share common elements such as screening, supervision and follow-up, but they should not be presented as interchangeable. Each has distinct indications, contraindications, monitoring requirements and levels of evidence. Spravato follows a regulated treatment pathway, while IV ketamine is generally used off-label and psilocybin therapies remain largely investigational. Importantly, careful screening and clinical monitoring reduce risk but do not eliminate it.
— Dr. Amy Reichelt, PhD, neuroscientist, chartered psychologist and psychotherapist, PsyAccess medical reviewers
Frequently asked questions
Is Spravato reimbursed in Slovakia?
No. It is registered but not categorised, after NIHO recommended refusal unless the indication narrowed and the maker discounted the price. The only public-money path is a case-by-case insurer exception, which you have no legal right to receive.
How do I apply for an exception?
You don't: your treating psychiatrist does, with a prior-approval request to your insurer. Documented failure of at least two adequate antidepressant trials is the core of the file. Approval rates for Spravato are not published; be prepared for refusal and ask about appeal options.
Can I get ketamine infusions in Slovakia?
Not through any publicly advertised programme. TMS clinic in Bratislava names ketamine infusion therapy as an alternative for treatment-resistant depression, but publishes no ketamine service; ask directly what they actually provide and who supervises it. Many patients look at Czech self-pay programmes instead.
Could the situation change?
NIHO itself proposed reassessment two years after any categorisation, and a renewed application with a deeper discount could succeed, but nothing public suggests a change is imminent. Watch NIHO's published projects and the categorisation lists rather than press releases.
Coming from another country? Whether a clinic will take a non-resident self-pay patient, what a Spravato induction schedule means for a visitor, and where cross-border treatment actually works: ketamine & psychedelic therapy in Europe for international patients.
Sources
- NIHO: Assessment summary No. 10 — esketamine (Spravato) for treatment-resistant depression
- NIHO: Full esketamine assessment report (PDF)
- Union health insurer: Reimbursement of registered non-categorised drugs — the exception mechanism
- ÚDZS: Exception-drug rules need clarification and legislative amendment (July 2023)
- ŠÚKL: Spravato (esketamine) patient booklet (PDF)
- TMS clinic, Bratislava: Frequently asked questions — TMS and ketamine infusion therapy as alternatives in resistant depression
- TMS clinic, Bratislava — private psychiatric clinic for treatment-resistant conditions
- Denník N: A first-person account of ketamine treatment for depression (2023)
- EMA: Spravato (esketamine) EPAR
This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Categorisation and exception rules change; always verify current requirements with your insurer, ŠÚKL, or a licensed clinician who knows your history. If you are in crisis, contact your local emergency number or a crisis line immediately.
This guide awaits review by a licensed medical professional.